Michal Kiciński

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank et al. · JAMA Oncology · 2020 · 421 citations · Full text

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 364 citations · Full text

Surgical Oncology, Medicine, Melanoma +8

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · Journal of Clinical Oncology · 2020 · 268 citations · Full text

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean-Jacques Grob et al. · European Journal of Cancer · 2019 · 170 citations

Surgical Oncology, Medicine, Melanoma +8

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma

Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank et al. · NEJM Evidence · 2022 · 142 citations

Surgical Oncology, Distant Metastasis, Medicine +15